Inspection included drug device combinations covering our recent filing in nasal sprays domain
Glucon-D maintained its leadership position with a 59% MAT market share
The Union Budget 2026–27 accords strong priority to the upgradation and expansion of healthcare infrastructure and medical education
The approval expands the drug’s existing COPD indication, making it the only single-inhaler triple therapy (SITT) available for both respiratory conditions in China
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The collaboration centers on the "Life Doesn't Stop for a Hot Flash" campaign
Developed using STEERLife’s proprietary FragMelt continuous processing platform, the approval marks a major breakthrough in pharmaceutical manufacturing
MH002, a rationally designed live microbial consortium, combines six well-characterized commensal strains to target disease-specific mechanisms
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
Subscribe To Our Newsletter & Stay Updated